The discovery of endogenous D-serine in the mammalian brain between 1990 and 1991 by the present author with my collaborators at the National Institute of Neuroscience, NCNP, in Tokyo and other institutes, was a consequence of my research project on the pathophysiology and novel pharmacotherapy of schizophrenia using D-serine and D-alanine, which facilitate the N-methyl-D-aspartate (NMDA) glutamate receptor function via its glycine site ( Fig. 1) , by noting the induction of schizophrenia-like psychosis by the glutamate receptor antagonists such as phencyclidine (PCP). [1] [2] [3] [4] [5] According to this author's idea to overcome the low ability of these polar D-amino acids to cross through the blood brain barrier (BBB) that their apolar compounds could easily permeate the BBB and improve the schizophrenic symptoms by their systemic administration, Dr. Hibino at Nippon Oil and Fats, Co., Ltd., designed and synthesized for our experiments, N-myristoyl-D-serine and N-myristoyl-D-alanine, which were shown to ameliorate an animal model of schizophrenia, PCP-induced abnormal behavior, following their intraperitoneal injection. 3, 6) During the process of the verification of the expected presence of free D-serine or D-alanine in the brain of animals treated with their fatty acid compounds by collaboration with the late Dr. Hayashi at the National Institute of Neuroscience and Dr. Fujii at Tsukuba University, we provided the first evidence that free D-serine is constantly maintained at a high concentration in the mammalian brain 7, 8) although D-amino acids were believed to be uncommon in mammalian tissues based on previous studies. 9) Through immediate confirmations 10, 11) of our findings, subsequent studies on endogenous D-serine have been gradually extended in a variety of aspects. In this article, the present status and future problems are discussed.
DISTRIBUTION AND METABOLISM OF ENDOGE-NOUS D-SERINE IN THE MAMMALIAN BRAIN

1) Distribution
In mature rats, D-serine is predominantly concentrated in the brain, 8) and its contents in the spinal cord, each peripheral tissue, or the blood are very low 8) (but high in the urine 12) ). The D-serine distribution in the brain is also uneven, showing high concentrations in the forebrain areas including the cerebral cortex, hippocampus, striatum, and limbic forebrain, moderate to low concentrations in the diencephalon and midbrain, and trace levels in the ponsmedulla and cerebellum.
8) The forebrain-preferred distribution of D-serine is positively correlated with those of the glutamate, PCP, and glycine sites of the NMDA receptor and particularly with that of the NMDA receptor R2B subunit mRNA. 8, 13) These characteristics of the endogenous D-serine distribution have been ascertained by subsequent biochemical 11, 14, 15) and immunohistochemical studies using the anti-Dserine antibody, [16] [17] [18] and proved to be common to humans The NMDA receptor complex has the multiple regulatory binding sites for glutamate (Glu), glycine and D-serine (Gly), magnesium ions (Mg ϩϩ ), phencyclidine (PCP), and polyamine (Poly). This heteromeric receptor consists of an NR1 subunit (there are various variants) and at least one of 4 types of the NR2 subunits, A-D. Gly is considered to be present on NR1 and Glu on NR2. The more recently identified NR3 subunit could have regulatory sites that differ from those shown in this scheme. and other mammalians. 11, 14, 19, 20) At the cell level, [16] [17] [18] a Dserine-like immunoreactivity has been described in astrocytes, oligodendrocytes and the cell bodies, dendrites, and axons of neurons.
The D-serine distribution in the brain significantly changes with postnatal development, 8, 14, 15, 21) and is almost homogenous immediately after birth but approaches the pattern of the mature stage during the 3-week period after birth in the rat. 8, 14, 21) These developmental changes are also similar to those for the distribution of the R2B subunit mRNA in the brain. 8, 13, 14, 21) 2) Extracellular Release D-Serine is detected in extracellular fluid by an in vivo dialysis technique in the medial frontal cortex, striatum and cerebellum. 22) The extracellular contents of D-serine are closely correlated with its concentration in tissue (about 5ϫ10 Ϫ6 M in the cortex of the medial frontal cortex) and the NMDA receptor distribution. 22) Unlike classical neurotransmitters, such as glutamate, glycine and dopamine, the amount of D-serine in the frontal extracellular fluid was not increased, but rather decreased, by depolarization following a veratrine or high concentration of potassium ion application. 22) Furthermore, the interruption of the nerve impulse flow or removal of extracellular calcium ions failed to reduce the extracellular D-serine levels. 22) In vitro studies using cultured astrocytes from the rat cerebral cortex or C6 glioma cells 16, 23) indicate that kainite-and AMPA ((S)-a-amino3-hydroxy-5-methyl-4-isoxazolepropionic acid) induce the D-serine release. In contrast to the spontaneous liberation, this evoked release is shown to be dependent upon the calcium ion and SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) protein as other transmitters released from the astroglial cells including glutamate and ATP. 23) The relationship between the evoked and the basal (spontaneous) release of D-serine awaits further elucidation.
3) Uptake Rat brain homogenates [24] [25] [26] and C6 cells 27) have been demonstrated to have a sodium-dependent or -independent, saturable and temperature-sensitive uptake activity for D-serine. The pharmacological characteristics of the D-serine uptake by rat brain homogenates differ from those of the uptake of known transporters. Although a specific and physiological transporter for D-serine has not yet been identified, it is of interest to note that the sodium-independent neutral amino acid transporter Asc1 shows a high affinity not only to L-serine, L-cysteine, and L-alanine, but also to D-serine.
28)
4) Synthesis
In the rat brain, the augmented concentration of L-serine by its systemic administration results in an increase in the D-serine content, and vise versa. 29 30) These phenomena suggest the presence of a serine racemase that catalyzes the synthesis of D-serine from L-serine. Indeed, a pyridoxal 5Ј-phosphate-dependent serine racemase with D-and L-serine a,b-elimination activities has been reported in rat and human tissues. 31, 32) However, it cannot be excluded that D-serine biosynthesis might be regulated by other enzymes, such as a phosphoserine phosphatase, glycine cleavage system and serine hydroxymethyl transferase, because of 1) the formation of D-serine from L-phosphoserine in brain synaptosomes, 33) 2) a reduction in the D-serine contents in the cerebral cortex of patients with non-ketotic hyperglycinemia lacking the glycine cleavage system and of the rat treated with an inhibitor of this enzyme system, 34) and 3) an increase in the brain D-serine concentrations by application of glycine. 29) 5) Degradation A long-known mammalian enzyme, Damino acid oxidase (DAO), has a D-serine degradation activity. 35, 36) In the rat brain, the distribution and its postnatal development of DAO are inversely correlated with those of D-serine; the DAO activity rapidly increases in the cerebellum, pons, and medulla oblongata about 10 d after birth, 36, 37) when the D-serine concentration begins to decrease. 14, 21) In mutant mice lacking this enzyme activity, there is a marked and very slight increase in D-serine contents in the cerebellum and cerebral cortex, respectively. 37) These findings indicate the involvement of DAO in the formation of a D-serine concentration gradient in the brain, and, at least, in the D-serine degradation in the metencephalon. A very slight activity, 37) mRNA expression 39) and immunoreactivity 16, 37) of DAO in the forebrain tissues or astrocytes cultured from the rat cerebral cortex do not deny the possible presence of other enzymes that catalyze the physiological D-serine degradation in the forebrain areas.
6) D-Serine Responsive Novel Genes
We have recently isolated two novel transcripts, dsr-1 (D-serine-responsive transcript-1) 40) and dsr-2, 41) of which the expressions are selectively induced by D-serine but not by L-serine. A part of dsr-1 is homologous with the M9.2 gene that encodes the proton ATPase subunit, suggesting its possible involvement in the D-serine uptake and release. 40) Also, dsr-2 seems to be involved in the metabolism or functions of D-serine, because the mRNAs of dsr-2 are exclusively expressed in the brain and show a D-serine-and NMDA receptor R2B subunit-like distribution in the brain. (Fig. 1) : Before D-serine was found to be an endogenous substance, this D-amino acid was initially known as a selective agonist for the glycine-binding site of the NMDA receptor. 42) Like glycine and D-alanine, D-serine stimulates the glycine site of the NMDA type receptor consisting of NR1 and NR2 subunits and enhances the action of glutamate on the receptor as follows 42) : (a) depolarization, (b) inward electric current, (c) Ca ϩϩ inflow, (d) cGMP production, (e) release of various neurotransmitters, and (f) neuron death. Stimulation of the glycine modulatory site alone does not induce excitatory postsynaptic potentials, but is indispensable for adequate neurotransmission by glutamate. 42) Consequently, glycine, D-serine, and D-alanine are called "co-agonists" for the NMDA receptor. 42) The actions of the two D-amino acids are stereoselective and much more potent than the respective L-amino acids. 42) Together with these characteristic actions, the NMDA receptor-like distribution of D-serine in the mammalian brains (see 1.-1)) suggests that D-serine in the brain is a physiological co-agonist for the NMDA receptor. 8) Glycine is another intrinsic co-agonist of the NMDA receptor with a different distribution pattern and metabolic pathway in the brain from D-serine and/or the NMDA receptor 8) ( Table 1 ). The neurobiological differences indicate the distinct physiological roles between D-serine and glycine in the control of the NMDA receptor, which are still unclear ( Table 1) .
The pivotal role of D-serine in the NMDA receptor activation is supported by the fact that in the hippocampal slice preparation, selective depletion of the endogenous D-serine in the hippocampal slice preparation by DAO results in a marked inhibition of the NMDA receptor-mediated spontaneous and evoked synaptic currents, 43) nitric oxide synthase activation, 43) cGMP production 43) and long-time potentiation (LTP) induction 44) without significant changes in the glycine contents. The 4 types of heteromeric NMDA receptors in any combination with NR2A-NR2D and NR1 that are expressed on the Xenopus oocytes displayed no differences in responses to D-serine and glycine. 45) The enhancing effect of Dserine on the glutamate-induced inward current was several times as potent as that of glycine in each type of receptor. 45) ii) NMDA Receptors Composed of NR1 and NR3 Subunits: Heteromeric NMDA receptors composed of NR1 and NR3A or NR3B respond to neither glutamate nor NMDA, but glycine induces excitatory responses (inward current). 46) Interestingly, D-serine shows an action opposite to that of glycine in the NR1/NR3 NMDA receptors, having negligible effects when used alone, but markedly blocking the glycineinduced inward currents. 46) Therefore, D-serine is also a candidate as an endogenous modulator for NR1/NR3 type NMDA receptors, but not a co-agonist.
2) Glia/Neuron Interaction The lack of increase in the levels of the extracellular D-serine following depolarization stimuli 23) and a substantial D-serine-like immunoreactivity in the glia cells including astrocytes 16, 18) suggest that D-serine may be released as a neuromodulator from these glia cells. Several studies indeed reported the presence of a serine racemase-like immunoreactivity, 23, 31) uptake 16) and release 16, 23) activity of D-serine and DAO mRNA 39) in the astrocyte. The D-serine synthesis in the astrocytes is also indicated to depend on the co-existence of neurons in the culture system. 44) These observations are consistent with the idea that D-serine may be implicated in the glia-neuron interaction that is required for the control of the NMDA receptor in the brain, although its exact cellular setups remain to be clarified.
3) Neural Circuit Formation
In the cerebellar slices, D-serine is shown to enhance granule cell migration while the selective degradation of D-serine by DAO and pharmacologic attenuation of the serine racemase activity hamper the process. 47) These phenomena suggest the involvement of brain D-serine in neural circuit formation possibly via the NMDA receptors in a certain growth stage or during repair of the nerve wiring.
D-SERINE AND NEUROPSYCHIATRIC DISORDERS
1)
Implications for the Pathophysiology D-Serine, a putative endogenous co-agonist for the NR1/NR2 type NMDA receptor, is supposed to play a critical role in the development and control of various higher brain functions in which NMDA receptors are involved. Therefore, disturbances in the brain D-serine and the molecular system for its metabolism and function may induce a variety of neuropsychiatric symptoms. Indeed, substances including D-serine that act on the glycine site of the NMDA receptor influence schizophrenic symptoms 48) and their animal models, [1] [2] [3] [4] [5] 49) cerebral ataxia, 50, 51) the action of alcohol, 42) learning ability in dementia model animals, 42) anxiety behavior, 42) convulsion threshold, 42) ischemic neuron death, 42, 52) and long-term behavioral abnormalities due to drug dependence. 42) A drastic reduction in the brain D-serine contents was found in patients with non-ketotic hyperglycinemia 34) lacking the glycine cleavage system who presented various central nervous symptoms such as mental retardation, convulsive attacks, apnea, and drowsiness. Particularly, attention has recently been directed to the possible association of endogenous D-serine with the pathophysiology of schizophrenia.
NMDA receptor antagonists acting at the PCP and glutamate site induce schizophrenia-like psychosis exhibiting both /Neuromodulator CNS, central nervous system; NR, NMDA receptor; NR-associated glycine site, strychnine-insensitive glycine receptor (cf. inhibitory glycine receptor, strychnine-sensitive glycine receptor). a) Note that glycine alone has been reported to induce the excitatory responses in the NR1/NR3 type heteromeric NR receptor.
positive (e.g., hallucination and delusion) and negative (e.g., affective flattening, alogia and avolition) symptoms in proportion to the potency of the blocking action. 1, 48) In contrast, various symptoms in patients with schizophrenia have been demonstrated to be improved by the oral administration of glycine, D-cycloserine, or D-serine which facilitate the NMDA receptor function by stimulating the glycine modulatory site of the glutamate receptor. 48) Based on these observations, it is widely accepted that glutamate neurotransmission via the NMDA receptor may be decreased in schizophrenia. 48) One possible cause of this decrease is the reduced activation of this receptor due to a deficit in the D-serine signals conveyed to the glycine site resulting from abnormalities in molecules crucial for the metabolism or function of the brain D-serine, although no direct evidence for this hypothesis has been so far provided. There are no reports describing significant changes in the D-serine concentrations in the postmortem brain tissues from the patients with schizophrenia as compared to those without neuropsychiatric disorders. 11, 20) However, in the postmortem schizophrenic brains, an increase in the NMDA glycine binding sites was observed in some cerebral cortical areas, 54) which might be compensatory responses to the decreased extracellular D-serine release in the specific neural circuit. In addition, the association of single-nucleotide polymorphism markers from both the DAO gene and a new gene G72 from chromosome 13q34 with schizophrenia, together with an in vitro augmentation of DAO activity by a G72 protein product, 55) suggest an altered D-serine metabolism in this disorder.
2) Implications for the Development of Novel Pharmacotherapy Clinical studies have been performed to apply the anti-psychotomimetic 1,-5,49,55) and anti-ataxic 50, 51) actions of D-serine or other agonists for the NMDA glycine site, which are proven in animal experiments, to the treatment of schizophrenia and cerebellar ataxia. As expected by the ability of NMDA antagonists to induce schizophrenialike antipsychotic-insensitive symptoms, the glycine agonists including glycine, D-cycloserine, D-serine and a glycine transporter inhibitor, N-methylglycine, have been found to ameliorate the schizophrenic symptoms that are resistant to conventional pharmacotherapy. 48) We reported that a NMDA glycine site agonist, D-cycloserine, improved some ataxic movements in patients with spinocerebellar degeneration 50) for which there are few effective treatment drugs. The above clinically applicable NMDA receptor potentiators, however, have problems in the effective administration doses 48) and side effects. 56) Advances in the research on molecular mechanisms of the D-serine metabolism in the brain may allow a search for D-serine signal regulatory drugs targeting D-serineassociated molecules, such as D-serine-specific transporter inhibitors, and also overcome these problems.
CONCLUSION
Compelling evidence has been accumulated indicating that brain D-serine is a neuromodulator for, at least, the NMDA type glutamate receptor (Table 1) and is involved in a neuron-glia interaction, wiring and rearrangement of neuron circuits and behavioral expression in mammals. The NMDA coagonist nature of D-serine suggests that the endogenous D-amino acid should be maintained above a certain concentration in synaptic clefts for the physiological glutamate transmission via the NMDA receptor and requires a distinct molecular and cellular system from those for classical neurotransmitters that should be rapidly removed after their quantal release in the synaptic clefts. This hypothesis appears to be consistent with the data showing the unique profiles of release, uptake and disappearance of D-serine in the brain tissues which are not seen in the other known neuroactive substances. Therefore, clarifying the molecular mechanisms of the metabolism and physiological function of the brain D-serine is expected to lead to not only new physiochemical findings, but also clues to unknown information processing systems controlling the brain functions, which may markedly promote the understanding of the cause/pathology of neuropsychiatric disorders and the development of new treatment methods.
